Brief: 60 Degrees Pharma Withdraws COVID IND For Phase IIB Study

60 Degrees Pharmaceuticals

18/09/2023 22:29

Sept 18 (Reuters) - 60 Degrees Pharmaceuticals Inc
 SXTP.O :
    * 60 DEGREES PHARMA WITHDRAWS COVID PHASE IIB IND, WILL
RESUBMIT
PENDING ASSESSMENT OF ABILITY TO MEET FDA REQUIREMENTS
    * 60 DEGREES PHARMACEUTICALS INC - COMPANY PLANS TO RESUBMIT
A
REVISED IND LATER IN 2023, PENDING A FEASIBILITY ASSESSMENT
    * 60 DEGREES PHARMACEUTICALS INC - 60P AUSTRALIA PTY LTD, A
MAJORITY-OWNED SUBSIDIARY OF 60 DEGREES PHARMACEUTICALS, HAS
WITHDRAWN ITS IND FOR ACLR8-LR
    * 60 DEGREES PHARMACEUTICALS INC - 60P HAS PAUSED FURTHER
STUDY
START-UP PREPARATIONS RELATED TO ACLR8-LR, DECREASING COMPANY'S
SHORT-TERM BURN RATE
    * 60 DEGREES - WILL CONTINUE PLANNED EFFORTS TO EXPAND ITS
MALARIA
BUSINESS AND PREPARE AN IND FOR TAFENOQUINE FOR BABESIOSIS TO BE
SUBMITTED TO FDA
    * 60 DEGREES - 60P WILL CONTINUE PLANNED EFFORTS TO EXPAND
ITS
MALARIA BUSINESS AND PREPARE AN IND FOR TAFENOQUINE FOR
BABESIOSIS TO BE SUBMITTED TO FDA
    * 60 DEGREES PHARMACEUTICALS INC -  60P INTENDS TO SUBMIT A
NEW
IND IN Q4
    * 60 DEGREES PHARMACEUTICALS INC - COMPANY'S DECISION TO
WITHDRAW
IND IS IN RESPONSE TO RECENT COMMENTS FROM U.S. FOOD AND DRUG
ADMINISTRATION

Source text for Eikon:  ID:nGNXqqMfQ 
Further company coverage:  SXTP.O 

 ((Reuters.Briefs@thomsonreuters.com;))